Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Madrigal Pharmaceuticals (MDGL) Times Interest Earned (2022 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Times Interest Earned for 4 consecutive years, with -$7.18 as the latest value for Q4 2025.

  • On a quarterly basis, Times Interest Earned rose 62.48% to -$7.18 in Q4 2025 year-over-year; TTM through Dec 2025 was -$13.45, a 60.36% increase, with the full-year FY2025 number at -$13.45, up 60.36% from a year prior.
  • Times Interest Earned was -$7.18 for Q4 2025 at Madrigal Pharmaceuticals, up from -$15.3 in the prior quarter.
  • In the past five years, Times Interest Earned ranged from a high of -$7.18 in Q4 2025 to a low of -$90.09 in Q2 2022.
  • A 4-year average of -$34.08 and a median of -$29.8 in 2023 define the central range for Times Interest Earned.
  • Peak YoY movement for Times Interest Earned: plummeted 49.19% in 2024, then skyrocketed 67.47% in 2025.
  • Madrigal Pharmaceuticals' Times Interest Earned stood at -$50.71 in 2022, then soared by 41.81% to -$29.51 in 2023, then soared by 35.11% to -$19.15 in 2024, then soared by 62.48% to -$7.18 in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Times Interest Earned are -$7.18 (Q4 2025), -$15.3 (Q3 2025), and -$14.46 (Q2 2025).